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Edited by Lukas HuberAbstract The farnesoid X receptor (FXR) is a nuclear
receptor activated by bile acids (BAs). In response to ligand-
binding, FXR regulates many genes involved in BA, lipid, and
lipoprotein metabolism. To identify new FXR target genes,
microarray technology was used to proﬁle total RNA
extracted from HepG2 cells treated with the natural FXR
agonist chenodeoxycholic acid (CDCA). Interestingly, a
signiﬁcant increase of transcript level of the very low density
lipoprotein receptor (VLDLR) was observed. Our data,
resulting from selective FXR activation, FXR RNA silencing
and FXR-deﬁcient mice, clearly demonstrate that BAs up-
regulate VLDLR transcript levels via a FXR-dependent
mechanism in vitro in human and in vivo in mouse liver cells.
 2004 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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The farnesoid X receptor (FXR; NR1H4) is a member of
the nuclear receptor superfamily that is expressed in liver,
kidney, intestine and the adrenal gland [1]. FXR is activated
by bile acids (BAs), such as the primary BA chenodeoxy-
cholic acid (CDCA), which is the most potent BA ligand for
the human FXR [2,3]. In addition to BAs, synthetic FXR
agonists have also been identiﬁed [4,5]. In response to li-
gand-binding, FXR regulates a variety of genes involved in* Corresponding author. Fax: +33-3-20-87-71-98.
E-mail address: bart.staels@pasteur-lille.fr (B. Staels).
Abbreviations: apo, apolipoprotein; BA, bile acid; BSEP, bile salt
export pump; CDCA, chenodeoxycholic acid; FA, fatty acid; FGF,
ﬁbroblast growth factor; FXR, farnesoid X receptor; FXRE, FXR
response element; HDL, high density lipoprotein; I-BABP, intestinal
bile acid binding protein; IR, inverted repeat; LPL, lipoprotein lipase;
LRH, liver receptor homolog; PFIC, progressive familial intrahepatic
cholestasis; PLTP, phospholipid transfer protein; PPAR, peroxisome
proliferator-activated receptor; SHP, small heterodimer partner; TG,
triglyceride; MDR, multidrug resistance gene; NTCP, Naþ-taurocho-
late transporting polypeptide; siRNA, small interfering RNA; TCA,
taurocholic acid; VLDLR, very low density lipoprotein receptor
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lism. Targeted disruption of the FXR gene in mice con-
ﬁrmed its critical role in BA and lipid metabolism [6]. FXR
links cholesterol to BA metabolism by inhibiting transcrip-
tion of the CYP7A1 gene [7], which encodes the rate-limiting
enzyme catalyzing the conversion of cholesterol into BAs.
FXR also regulates the expression of various genes involved
in the uptake, intracellular transport and export of BAs such
as intestinal BA-binding protein (I-BABP) [8], the bile salt
export pump (BSEP) [9] and the Naþ-taurocholate cotrans-
porting polypeptide (NTCP) [10]. Furthermore, FXR plays
an important role in lipoprotein and high density lipoprotein
(HDL) metabolism. FXR positively regulates the phospho-
lipid transfer protein (PLTP) gene [11], which encodes a
secreted protein that facilitates the transfer of phospholipids
between lipoproteins and modulates plasma HDL metabo-
lism. In addition, apo AI, the major apolipoprotein (apo)
component of HDL, is down-regulated by FXR [12]. FXR
also controls plasma TG levels by activating the peroxisome
proliferator-activated receptor a (PPARa) gene, another
nuclear receptor controlling TG metabolism [13], and the
apo CII gene [14], an obligate cofactor for lipoprotein lipase
(LPL) responsible for the hydrolysis of TGs in chylomy-
crons, and by inhibiting apo CIII [15], which plays an im-
portant role in the control of TG metabolism. More
recently, it has been demonstrated that FXR activates
transcription of the human multidrug resistance MDR3 gene
[16], encoding a P-glycoprotein which is a critical translo-
cator for phospholipids across canalicular membranes of
hepatocytes. As part of a systematic eﬀort to identify new
FXR target genes implicated in lipid metabolism, we per-
formed DNA microarray experiments on human hepato-
blastoma HepG2 cells treated with the natural FXR agonist
CDCA. We report here the identiﬁcation of the very low
density lipoprotein receptor (VLDLR) as a new target gene
for FXR in human and mouse liver cells.2. Materials and methods
2.1. Cell culture and treatments
Human hepatoblastoma HepG2 and HuH7 cells (American Type
Culture Collection, Rockville, MD) were grown in Dulbecco’s modiﬁedation of European Biochemical Societies.
174 A. Sirvent et al. / FEBS Letters 566 (2004) 173–177Eagle’s medium supplemented with 10% fetal calf serum, streptomycin/
penicillin, sodium pyruvate, glutamine and non-essential amino-acids
(LifeTechnologies, Cergy-Pontoise, France) at 37 C, in ahumidiﬁed5%
CO2 atmosphere. Human primary hepatocytes were isolated as de-
scribed [17] and incubated for 48 h with chenodeoxycholic acid (CDCA;
75 lM) (Sigma, Saint-Quentin, France) or GW4064 (1 lM). GW4064
was synthesized atGENFIT (Loos, France), according toMaloney et al.
[4]. FormRNAanalysis,HepG2 cells were treated in 6well plates at 60%
conﬂuence with either CDCA or GW4064 at the indicated concentra-
tion. For the actinomycin D and cycloheximide experiments, cells were
pre-treated during 1 h before adding FXR agonists for 36 h.2.2. Animals and treatments
FXR-deﬁcient mice, obtained as described previously [6], were
backcrossed for ﬁve generations in the C57BL/6 genetic background.
Male C57BL/6 wild-type mice (IFFA-CREDO, L’Arbresle, France)
and FXR-deﬁcient mice were divided into two groups of animals
(n ¼ 4 per group). One group received a standard rodent chow diet
(control), whereas the other group received the same diet containing
0.5% (wt/wt) taurocholic acid (TCA) (Sigma, Saint-Quentin, France)
for 5 days. Animals were killed at the end of the treatment, livers were
collected and frozen until further analysis.2.3. RNA analysis
Total RNA was isolated from cells and tissues using TRI-Reagent
according to the manufacturer’s instructions (Sigma, Saint-Quentin,
France). For gene expression analysis, total RNA was reverse tran-
scribed as described previously [18]. Real-time Quantitative PCR anal-
ysis was performed using the LightCycler Technology (Roche
Diagnostic) according to the manufacturer’s instructions. The PCR
program consisted of a denaturing step at 95 C for 8min followed by 40
cycles of 10 s at 55 C, 10 s at 95 Cand 15 s at 72 C.Primers usedwere as
follows : 36B4 forward 50-CATGCTCAACATCTCCCCCTTCTCC-30
and reverse 50-GGGAAGGTGTAATCCGTCTCCACAG-30; GA-
PDH forward 50-GACATCAAGAAGGTGGTGAA-30 and reverse
50-CCACATACCAGGAAATGAGC-30; human VLDLR forward
50-TGGTCGCTGTATTACGCTGTTG-30 and reverse 50-GGCACT-
GTTCTGGGCTTTCA-30; human FXR forward 50-CCGTGAA-
TGAAGACAGTGAAGGTCG-30 and reverse 50-ACCCTTTCAGCAA-
AGCAATCTGGTC-30; human small heterodimer partner (SHP) forward
50-GGCTGGCAGTGCTGATTCAG-30 and reverse 50-TGGGGTGT-
GGCTGAGTGAAG-30; mouse VLDLR forward 50-CTTGTAGA-
GCAACTAAGGAACACGG-30 and reverse 50-CAGTCTGAC-CAG-
TAAACAAAGCCC-30. Transcript levels were normalized to 36B4 RNA
levels.2.4. Gene silencing with small interfering RNA (siRNA)
The siRNA targeting human FXR with the cDNA sequence 50-
GTCGTGACTTGCGACAAG-30 was chemically synthesized by
Eurogentec (Seraing, Belgium) and annealed according to the manu-
facturer’s instructions. The siRNA negative control from Ambion
(Austin, US) was used to test non-speciﬁc eﬀects on gene expression.
HepG2 cells were transfected using oligofectamine (Invitrogen, UK)
according to the manufacturer’s instructions in 12-well plates con-
taining 150 103 cells/well with 125 nM siRNA/well. 12 h after
transfection, cells were treated for 24 h with FXR agonists at the in-
dicated concentrations before RNA analysis.2.5. DNA microarray analysis
HepG2 cells were cultured as described above and treated with 75
lM CDCA for 36 h. Total RNA (50 lg), isolated using TRI-reagent
(Sigma) and puriﬁed with RNeasy total RNA isolation kit (Qiagen),
was reverse transcribed by using a T7-(dT)24 primer (Genset Corp.)
and the superscript Choice system (Life-technologies). The resulting
cDNA was used to generate biotin-labelled cRNA with a bio-array
high-yield transcript labelling kit (Enzo). Fragmentation of cRNA
was performed at 94 C using 40 mM Tris–acetate (pH 8.1), 100
mM potassium acetate, and 30 mM magnesium acetate. Samples
were hybridized according to the manufacturer’s instructions to
Aﬀymetrix human U95Av2 microarrays in triplicate for each treat-
ment. The results of the microarrays were analyzed with Microarray
Analysis Suite 4.0 software (Aﬀymetrix).3. Results
3.1. FXR agonists induce VLDLR transcript levels in human
liver cells
To identify new FXR target genes, we used a global genomic
approach by performing a DNA microarray experiment.
HepG2 cells were treated with vehicle or the natural FXR li-
gand CDCA (75 lM) for 36 h. Total RNA was submitted to
microarray analysis on human U95Av2 Aﬀymetrix arrays
(n ¼ 3). Analysis of the results (data not shown) revealed
regulation of several known FXR target genes by CDCA
treatment, including SHP (2.7-fold), apoAI (3-fold) and MRP3
(5.4-fold). In addition, the microarrays showed a 2.1-fold in-
duction of VLDL receptor RNA. In line with this observation,
a signiﬁcant dose-dependent increase of VLDLR RNA levels
was observed inHuH7 cells treatedwith various doses of CDCA
for 36 h (Fig. 1A). Since BAs may exert FXR-independent
eﬀects by activating other signal transduction pathways
[19,20], the inﬂuence of the synthetic non-steroidal FXR spe-
ciﬁc agonist GW4064 on VLDLR transcript expression was
tested. Treatment of HepG2 cells with GW4064, as well as
CDCA, resulted in an increase of VLDLR transcript levels
compared to control vehicle-treated cells (Fig. 1B). Moreover,
up-regulation of VLDLR RNA levels also occurred in primary
human hepatocytes treated with CDCA and GW4064
(Fig. 1C). Taken together these data demonstrate that FXR
agonists up-regulate VLDLR RNA levels in human liver cells.
3.2. Induction of VLDLR transcript levels by FXR agonists
requires ongoing transcription and protein synthesis
In order to investigate in more detail the action mechanism
of FXR agonists on VLDLR transcript levels, a time course
experiment was performed in HepG2 cells (Fig. 2). The in-
duction of VLDLR transcript expression by CDCA occurred
very early, similar to the response of SHP expression to FXR
agonists [18]. Furthermore, pretreatment with either actino-
mycin D, an inhibitor of transcription (Fig. 3A), or cyclo-
heximide, a translation inhibitor (Fig. 3B), completely
abolished the induction of VLDLR RNA levels in HepG2 cells
by CDCA. These results indicate that FXR agonists induce the
expression of the VLDLR gene at the transcriptional level by a
mechanism requiring de novo protein synthesis.
3.3. CDCA- and GW4064-mediated up-regulation of VLDLR
transcript levels occurs by an FXR-dependent mechanism
To determine whether the regulation of VLDLR gene ex-
pression by FXR agonists observed in human liver cells is
dependent on FXR activation, a FXR gene silencing experi-
ment was performed using speciﬁc siRNA duplexes to reduce
expression of FXR transcript prior to treatment with FXR
agonists. A negative siRNA was used to control non-speciﬁc
eﬀects of the transfection on gene expression. Compared to
control cells, transfection of HepG2 cells with the FXR-
speciﬁc siRNA reduced the level of FXR RNA by about 80%
(Fig. 4A), whereas there was no eﬀect on GAPDH RNA levels
(Fig. 4B). As a positive control, the levels of SHP transcript
were quantiﬁed in the same samples (Fig. 4C), and as expected,
FXR ligand treatment increased SHP levels in control cells
treated with FXR agonists, but not in FXR knockdown cells.
Interestingly, FXR silencing abolished the CDCA- and
GW4064-mediated up-regulation of VLDLR RNA (Fig. 4D).
Taken together these results demonstrate that FXR mediates
Fig. 1. Natural and synthetic FXR agonists enhance VLDLR transcript levels in human liver cells. (A) HuH7 cells were treated for 36 h with in-
creasing concentrations of CDCA (as indicated in the ﬁgure). HepG2 cells (B) and primary human hepatocytes (C) were treated with DMSO (ctrl),
CDCA (75 lM) or GW4064 (1 lM) for 36 and 48 h, respectively. VLDLR transcript levels were measured by real-time quantitative PCR. Values are
meansS.D. (n ¼ 3). Statistically signiﬁcant diﬀerences between control and FXR agonists-treated cells are indicated by asterisks (Student’s t-test:
***, P < 0:001; **, 0:001 < P < 0:01; and *, 0:01 < P < 0:05).
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Fig. 2. CDCA induces VLDLR transcript levels in HepG2 cells in a
time-dependent manner. HepG2 cells were treated with DMSO (ctrl)
or CDCA (75 lM) for 6, 12, 24 and 48 h. VLDLR transcript levels
were measured by real-time quantitative PCR. Values are
meansS.D. (n ¼ 3) and each time point was normalized to control
set as 100%. Statistically signiﬁcant diﬀerences between control
and CDCA-treated cells are indicated by asterisks (Student’s t-test:
***, P < 0:001).
A. Sirvent et al. / FEBS Letters 566 (2004) 173–177 175the up-regulation of VLDLR transcript levels by CDCA and
GW4064 in HepG2 cells.
3.4. Bile acids induce VLDLR RNA levels in vivo in the liver of
wild type but not FXR-deﬁcient mice
To determine if the FXR-dependent regulation of VLDLR
gene expression observed in vitro in liver cells also occurs in
vivo, wild type and FXR-deﬁcient mice were treated for 5 days200
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Fig. 3. CDCA- and GW4064-mediated up-regulation of VLDLR transcrip
cells were incubated with CDCA (75 lM) or GW4064 (1 lM) for 24 h, in th
10 (lg/ll) (B). VLDLR transcript levels were measured by real-time quant
diﬀerences between control and FXR agonists-treated cells are indicated bywith TCA, and VLDLR RNA levels were analyzed in the liver.
VLDLR transcript levels were not signiﬁcantly diﬀerent in
livers of wild type versus FXR-deﬁcient mice under normal
feeding conditions (100% versus 89%, student’s t-test:
P ¼ 0:832). However, in wild-type mice BA treatment induced
the expression of VLDLR transcript, whereas in FXR-
deﬁcient mice VLDLR RNA levels did not change signiﬁcantly
(Fig. 5). Taken together these data indicate that BAs regulate
VLDLR gene expression in mouse liver in vivo via activation
of FXR.4. Discussion
The results from this study indicate that VLDLR gene ex-
pression is regulated by an FXR-dependent mechanism both in
vitro in human and in vivo in mouse liver cells. A DNA mi-
croarray gene expression proﬁling approach was used to
identify new target genes of FXR agonists and the VLDL re-
ceptor was identiﬁed as a FXR target gene in the liver. This
was unexpected since VLDLR is expressed at high concen-
trations in skeletal muscle, heart, adipose tissue, brain and
macrophages, but is found only in trace amounts in the liver
[21,22]. The VLDLR has been described to bind apo E-rich
VLDL and LPL [23]. Recent reports have proposed several
possible functions of the VLDLR in lipoprotein metabolism
[24], atherosclerosis [25], obesity and insulin resistance [26],ctrl CDCA GW4064
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Fig. 4. Knockdown of FXR RNA levels abolishes the up-regulation of VLDLR transcript levels by FXR agonists in HepG2 cells. HepG2 cells were
transfected with siRNA duplexes speciﬁc for FXR or a siRNA negative control, and treated with DMSO (ctrl), CDCA (75 lM) or GW4064 (1 lM)
for 24 h. FXR (A), GAPDH (B), SHP (C) and VLDLR (D) transcript levels were measured by real-time quantitative PCR. Values are meansS.D.
(n ¼ 3). Statistically signiﬁcant diﬀerences are indicated by asterisks (Student’s t-test: ***, P < 0:001; **, 0:001 < P < 0:01; and *, 0:01 < P < 0:05;
and NS: not signiﬁcant).
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Fig. 5. Bile acid treatment induces VLDL receptor transcript levels in
livers of wild-type but not FXR deﬁcient mice. Mouse VLDLR
(mVLDLR) transcript levels were measured by real-time quantitative
PCR in livers of C57BL/6 wild type (FXR +/+) and FXR deﬁcient
(FXR )/)) mice fed with a standard rodent chow diet containing or
not TCA (0.5% TCA wt/wt) for 5 days. Values are meansS.D.
(n ¼ 4). Statistically signiﬁcant diﬀerences between control and
TCA-treated samples are indicated by asterisks (Student’s t-test:
**P < 0:001; and NS: not signiﬁcant).
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tion [28]. Although, relatively little is known about VLDLR
function in the liver, adenovirus-mediated overexpression of
the VLDLR into LDLR-deﬁcient mice liver showed a beneﬁ-
cial eﬀect on lipoprotein metabolism and atherosclerosis [29].
Initial studies on VLDLR-deﬁcient mice revealed no alter-
ations in lipoprotein proﬁle, total plasma cholesterol, TG and
free FA levels as compared to wild-type mice [30]. However,
when VLDLR transgenic and deﬁcient mice were studied un-
der conditions of LDLR deﬁciency, fed a high fat-diet or
subjected to prolonged fasting [31], VLDLR overexpression
was associated with a decrease, whereas VLDLR deﬁciency
was associated with an increase in plasma TG levels. In the
absence of the VLDLR, the lipid composition of nascent
VLDL was unaﬀected, but circulating VLDL displayed a high
TG content suggesting that the VLDLR modulates peripheral
TG metabolism. BA-sequestering resins, that are used for the
treatment of hypercholesterolemia, also increase plasma TG
due to accumulation of VLDL particles enriched in TG [32,33].
Because these resins interrupt the enterohepatic circulation of
BAs, treatment with these drugs is likely to decrease the ex-
posure of hepatocytes to BAs, thus potentially dampening
FXR activity and subsequently decreasing activation of FXR
target genes, such as the VLDLR. It is tempting to speculate
that such a decrease in VLDLR expression would contribute
to the observed changes in lipid metabolism after resin treat-
ment. Of more pathophysiological relevance, induction ofVLDLR by FXR may occur under conditions of high intra-
hepatic BA concentrations, such as in progressive familial
intrahepatic cholestasis (PFIC) [34].
In this study, we have clearly demonstrated, by using a non-
steroidal FXR-selective agonist, FXR knockdown and FXR-
deﬁcient mice, that BAs up-regulate human VLDLR RNA
level via a FXR-dependent mechanism. However, in silico
A. Sirvent et al. / FEBS Letters 566 (2004) 173–177 177DNA sequence analysis and transient transfection assays with
the putative inverted repeat 1 (IR1) sites did not reveal the
existence of a functional FXR response element (FXRE) in the
human VLDLR promoter. Although, FXR may also bind in
vitro to various atypical FXREs [35] these observations sug-
gest that FXR does not directly regulate the VLDLR. In line
with this, the regulation of VLDLR by BA requires de novo
protein synthesis suggesting the existence of an indirect
mechanism, or a direct mechanism that requires the synthesis
of a very labile and essential coactivator. Several mechanisms
for indirect transcriptional regulation of FXR target genes by
BAs have been proposed. BAs can down-regulate CYP7A1 via
FXR-mediated induction of the SHP [7,36], which represses
expression of CYP7A1 by inhibiting the activity of liver re-
ceptor homolog (LRH-1). FXR directly regulates expression
of ﬁbroblast growth factor-19 (FGF-19), and in turn FGF-19
strongly suppresses expression of CYP7A1 in primary cultures
of human hepatocytes and mouse liver through a c-Jun N-
terminal kinase pathway [37].
In conclusion, this study identiﬁes VLDLR as a novel FXR
target gene in the liver. These results suggest a novel mechanism
by which BAs may modulate lipid and lipoprotein metabolism.
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